Experimental Evaluation of 3-Meta-Pyridine-1,2,4-Oxadiazole Derivative of Deoxycholic Acid as a Prototype of 5-Alpha-Reductase Inhibitors in In Silico and In Vivo Models
February 2023
in “
Russian Journal of Bioorganic Chemistry
”
New to Finasteride? There is a guide in the encyclopedia. Read the guide → Studysummary In an animal study, researchers observed that a newly synthesized deoxycholic acid derivative showed similar prostate protection effects to finasteride in Wistar rats while being less toxic.
Our plain-language summary. Not medical advice or a treatment recommendation. Consult a qualified healthcare professional before changing treatment. Full disclaimer
The study investigates a novel 5-α-reductase inhibitor derived from deoxycholic acid, designed to minimize the side effects of current drugs like finasteride. The compound, incorporating a 3-meta-pyridine-1,2,4-oxadiazole fragment, showed similar binding energy to 5-AR as finasteride in molecular docking studies. In vivo experiments on Wistar rats revealed that the compound, at 20 mg/kg, provided prostate protection comparable to finasteride at 10 mg/kg, while also reducing prostate proliferation. Notably, the new compound demonstrated lower toxicity, with an LD50 of over 1500 mg/kg in CD-1 mice, compared to 1060 mg/kg for finasteride, indicating its potential as a safer alternative for further preclinical trials.
